| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 08/23/2001 | WO2001061009A2 Polypeptides and nucleic acids encoding same |
| 08/23/2001 | WO2001061008A2 Polypeptides and nucleic acids encoding same |
| 08/23/2001 | WO2001060991A2 Human kinases |
| 08/23/2001 | WO2001060835A1 Purine derivatives |
| 08/23/2001 | WO2001060825A1 Pyrrolopyrimidinone derivatives, process of preparation and use |
| 08/23/2001 | WO2001060822A1 Amino acid derivatives and use thereof as nep, ace and ece inhibitors |
| 08/23/2001 | WO2001060821A1 Novel biarylcarboxamides |
| 08/23/2001 | WO2001060819A1 Novel isoxazole and thiazole compounds and use thereof as drugs |
| 08/23/2001 | WO2001060816A1 Kinase inhibitors |
| 08/23/2001 | WO2001060814A2 Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 08/23/2001 | WO2001060813A1 Beta-alanine derivatives and their use as receptor antagonists |
| 08/23/2001 | WO2001060808A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors |
| 08/23/2001 | WO2001060807A1 Aryloxyacetic acids for diabetes and lipid disorders |
| 08/23/2001 | WO2001060806A2 Substituted arylpyrazines |
| 08/23/2001 | WO2001060805A1 Pyrimidine-4-one derivatives as ldl-pla2 inhibitors |
| 08/23/2001 | WO2001060804A1 Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid |
| 08/23/2001 | WO2001060798A1 Amine derivatives for the treatment of apoptosis |
| 08/23/2001 | WO2001060786A1 Aminoalcohol derivatives |
| 08/23/2001 | WO2001060784A1 Aniline-derived ligands for the thyroid receptor |
| 08/23/2001 | WO2001060778A2 Aspirin-triggered lipid mediators |
| 08/23/2001 | WO2001060414A2 Genetic modification of the lung as a portal for gene delivery |
| 08/23/2001 | WO2001060408A2 Microcompetiton and human disease |
| 08/23/2001 | WO2001060400A2 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease |
| 08/23/2001 | WO2001060398A1 Drugs for ameliorating impaired glucose tolerance |
| 08/23/2001 | WO2001060384A1 Inhibition of mal-1, the keratinocyte lipid binding protein |
| 08/23/2001 | WO2001060375A2 Use of 7alpha-hydroxy-estradiol, 7alpha-hydroxy-dehydroepiandrosterone and 7alpha-hydroxy-pregnenolone derivatives for treating acute cellular degeneration |
| 08/23/2001 | WO2001060374A1 Use of paullone derivatives for making medicines |
| 08/23/2001 | WO2001060350A2 Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation |
| 08/23/2001 | WO2001060348A2 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| 08/23/2001 | WO2001060179A1 Improvements in or relating to solubilisation of flavonols |
| 08/23/2001 | WO2001012775A3 25 human secreted proteins |
| 08/23/2001 | WO2001010816A3 Substituted 2-dialkylaminoalkylbiphenyl derivatives |
| 08/23/2001 | WO2001008633A3 An improved form of form I celiprolol hydrochloride |
| 08/23/2001 | WO2001007436A3 Substituted oxoazaheterocyclyl compounds |
| 08/23/2001 | WO2000071508A3 Inhibitors of factor Xa |
| 08/23/2001 | WO2000059484A3 Use of arylalkanoylpyridazines |
| 08/23/2001 | WO2000056294A3 Carnitine supplemented diet to prevent sudden death syndrome in broiler breeder type poultry |
| 08/23/2001 | US20010016645 Vitazin antibody; treating angiogenesis or restenosis |
| 08/23/2001 | US20010016600 Method of treating cancer using dithiocarbamate derivatives |
| 08/23/2001 | US20010016596 Substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| 08/23/2001 | US20010016586 Use of organic compounds |
| 08/23/2001 | US20010016583 Therapeutic application of pro-apoptotic benzodiazepines |
| 08/23/2001 | US20010016576 Administering pyrimidine nucleotide precursor where respiratory chain dysfunction is caused by mutation, deletion, or rearrangement of mitochondrial DNA, cytotoxic cancer chemotherapy agents, aging |
| 08/23/2001 | US20010016575 Antisense modulation of human MDM2 expression |
| 08/23/2001 | US20010016570 Bone disorders |
| 08/23/2001 | US20010016338 DNA molecule encoding a variant alpha2B-adrenoceptor protein, and uses thereof |
| 08/23/2001 | US20010016336 Genetic engineered polypeptide |
| 08/23/2001 | US20010016207 Compounds such as N-(1-(cyanomethylcarbamoyl)cyclohexyl)-4-(piperazin-1-yl)-benzamide |
| 08/23/2001 | US20010016197 Cultivating a fungi of the basidiomycetes in a submerged culture on nutrient media, isolating the biomass of edible mushrooms from the culture broth, and drying at a range of 40-45 degrees celsius |
| 08/23/2001 | EP1143945A3 Carnitine supplemented diet to prevent sudden death syndrome in broiler breeder type poultry |
| 08/23/2001 | EP1143944A3 Use of arylalkanoylpyridazines |
| 08/23/2001 | DE10038110A1 Pharmazeutische Zusammensetzungen Pharmaceutical compositions |
| 08/23/2001 | DE10006309A1 Verfahren zur Identifizierung von Substanzen, die die Aktivität von hyperpolarisationsaktivierten Kationen-kanälen modulieren A method for identifying substances that modulate the activity of hyperpolarization-activated cation channels, |
| 08/23/2001 | CA2651825A1 Substituted arylpyrazines |
| 08/23/2001 | CA2400862A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors |
| 08/23/2001 | CA2400860A1 Aminoalcohol derivatives |
| 08/23/2001 | CA2400634A1 Genetic modification of the lung as a portal for gene delivery |
| 08/23/2001 | CA2400631A1 Beta-alanine derivatives and their use as receptor antagonists |
| 08/23/2001 | CA2400619A1 Purine derivatives |
| 08/23/2001 | CA2400537A1 Amino acid derivatives and use thereof as nep, ace and ece inhibitors |
| 08/23/2001 | CA2400360A1 Polypeptides and nucleic acids encoding same |
| 08/23/2001 | CA2400332A1 Polypeptides and nucleic acids encoding same |
| 08/23/2001 | CA2400206A1 Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation |
| 08/23/2001 | CA2400034A1 Human kinases |
| 08/23/2001 | CA2400021A1 Aryloxyacetic acids for diabetes and lipid disorders |
| 08/23/2001 | CA2398937A1 Substituted arylpyrazines |
| 08/23/2001 | CA2398706A1 Cytoprotective steroids (ii) |
| 08/23/2001 | CA2398691A1 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| 08/23/2001 | CA2397651A1 Amine derivatives for the treatment of apoptosis |
| 08/23/2001 | CA2397560A1 Use of paullone derivatives for making medicines |
| 08/23/2001 | CA2397458A1 Improvements in or relating to solubilisation of flavonols |
| 08/23/2001 | CA2397233A1 Biarylcarboxamides |
| 08/23/2001 | CA2395473A1 Microcompetiton and human disease |
| 08/22/2001 | EP1125977A1 Dermatan sulfate composition as antithrombotic |
| 08/22/2001 | EP1125942A1 Derivatives of 6-amino or 6-hydrazinosulfonyl-3-quinolyl phosphonic acids, process for their preparation and pharmaceutical compositions containing them |
| 08/22/2001 | EP1125941A1 Derivatives of 6-sulfamoyl-3-quinolyl phosphonic acids, process for their preparation and pharmaceutical compositions containing them |
| 08/22/2001 | EP1125940A1 Derivatives of aryl or heteroaryl quinolinylphosphonic acids, process for their preparation and pharmaceutical compositions containing them |
| 08/22/2001 | EP1125938A1 Protein kinase inhibitors for treatment of neurological disorders |
| 08/22/2001 | EP1125929A1 Method for making (-)-(2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester |
| 08/22/2001 | EP1125925A1 Amine derivatives for the treatment of apoptosis |
| 08/22/2001 | EP1125924A1 Intermediate for the synthesis of amlodipine, preparation process and corresponding utilization |
| 08/22/2001 | EP1125922A1 Pyrrolidine compounds and medicinal utilization thereof |
| 08/22/2001 | EP1125580A2 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors |
| 08/22/2001 | EP1125579A2 Uses of agrp-melanocortin receptor binding modulating compounds |
| 08/22/2001 | EP1124980A2 Method for the production of quercetin and isoquercetin derivatives |
| 08/22/2001 | EP1124964A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 08/22/2001 | EP1124959A1 Cell surface molecule-induced macrophage activation |
| 08/22/2001 | EP1124958A2 Corticosteroid synthesis-associated genes |
| 08/22/2001 | EP1124950A2 p53 ANTISENSE AGENT AND METHOD |
| 08/22/2001 | EP1124856A1 Conformation-specific anti-von willebrand factor antibodies |
| 08/22/2001 | EP1124850A1 12 human secreted proteins |
| 08/22/2001 | EP1124848A2 Transmembrane 4 proteins |
| 08/22/2001 | EP1124845A2 Phosphinate peptide analogs for the treatment of fibrotic disorders |
| 08/22/2001 | EP1124837A2 Novel macrolide antibiotics |
| 08/22/2001 | EP1124828A1 Pyrano, piperidino, and thiopyrano compounds and methods of use |
| 08/22/2001 | EP1124824A1 Chromenone and chromanone derivatives as integrin inhibitors |
| 08/22/2001 | EP1124815A1 Method for producing luteolin and luteolin derivatives |
| 08/22/2001 | EP1124814A1 Aromatic derivatives and iron complexes thereof for the use as normalising agents of the iron level |
| 08/22/2001 | EP1124811A1 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| 08/22/2001 | EP1124810A1 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents |